Background: Pre-exposure prophylaxis (PrEP) could provide protection from human immunodeficiency virus (HIV) infection in sexually active persons at risk. Limited data are available in Zimbabwe with regard to the perceptions about PrEP amongst female sex workers (FSWs).
Objectives: The aim of this study was to evaluate the knowledge levels of oral PrEP and the likelihood of its use amongst FSWs.
Method: This was a cross-sectional study in the peri-urban areas of Harare, Zimbabwe. Human immunodeficiency virus-negative FSWs were interviewed to assess their awareness of and likelihood to use PrEP. The relative importance index was used to evaluate the levels of knowledge and the likelihood of, and barriers to, PrEP use. A set of 10 questions was designed and validated that evaluated participants' understanding of PrEP. A bivariate logistic regression model was utilised to identify predictors of PrEP use.
Results: A total of 131 FSWs with a median age of 25 years (interquartile range: 21-31) participated in this study. Of the 71 (54%) FSWs who had heard about PrEP, 46 (35%) participants had adequate knowledge of its use. A total of 102 (78%) participants revealed that they would be willing to continuously use PrEP if it was provided free of cost. Increasing age of the participants was associated with an increase in the likelihood of using PrEP ( = 0.0033, = 0.038). More knowledge about PrEP increased the likelihood of its use ( = 0.21, = 0.0153). This likelihood increased amongst participants with an unprotected sexual intercourse encounter in the preceding 3 months ( = 0.0448, = 0.026).
Conclusion: Knowledge of PrEP amongst FSWs was low. To increase the uptake of PrEP, there is a need to further sensitise FSWs about this intervention. Programmes should also promote awareness training in FSW subgroups that are less likely to use PrEP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059237 | PMC |
http://dx.doi.org/10.4102/sajhivmed.v21i1.1039 | DOI Listing |
MCN Am J Matern Child Nurs
October 2024
Jillian Pintye is an Associate Professor at the University of Washington School of Nursing, Seattle, WA. Dr. Pintye can be reached at
Background: Injectable depot medroxyprogesterone acetate (DMPA) is the most common contraceptive choice among young women in Uganda, where HIV burden is high and HIV pre-exposure prophylaxis (PrEP) may be offered. For young women who choose to use both agents concurrently, it is unknown whether they will experience declines in BMD beyond those elicited by either product singly.
Methods: From 2018-2022, we conducted a 2-year prospective study with women ages 16-25 years in Kampala, Uganda desiring pregnancy and HIV prevention.
AIDS Care
December 2024
Faculty of Medicine and Health, School of Population Health - UNSW Sydney, Kensington, NSW, Australia.
The goal of this study was to evaluate characteristics associated with Pre-exposure Prophylaxis for HIV infection (PrEP) non-adherence or discontinuation in Brazil and assess the association between these outcomes and HIV seroconversion. We used linked national dispensing and pathology data to identify people aged 14+ years initiating PrEP in 2018. We estimated non-adherence using the proportion of days covered (PDC), defining non-adherence as PDC < 60%.
View Article and Find Full Text PDFInt Endod J
December 2024
School of Dentistry, The University of Queensland, Brisbane, Queensland, Australia.
Aim: All commercial chelating gels contain EDTA which reacts chemically with sodium hypochlorite (NaOCl). This research aimed to develop a non-EDTA clodronate gel and to measure physicochemical and functional gel properties of the novel and commercial gels.
Methodology: A 1.
BMC Womens Health
December 2024
Department of Public Health Institute of Tropical Medicine, Antwerp, Belgium.
Background: Adolescent girls and young women (AGYW) are disproportionately affected by HIV. Globally, in 2022, an estimated 4000 AGYW 15-24 were newly infected with HIV weekly, and nearly 78% of these infections occurred in sub-Saharan Africa. Oral Pre-Exposure Prophylaxis (PrEP) is a key HIV prevention option within an overall HIV combination prevention approach with an efficacy of over 90% when taken correctly.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!